Abeona Therapeutics (ABEO) vs Entrada Therapeutics (TRDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Abeona Therapeutics (ABEO) has outperformed Entrada Therapeutics (TRDA) over the past year, losing 46.0% versus a loss of 57.0%. Over five years, TRDA leads with a -85.0% price change compared with -86.7% for ABEO. Entrada Therapeutics is the larger company by market cap ($170.3 million vs $165.3 million), about 1.0 times the size.
Abeona Therapeutics converts more of its revenue into profit, with a net margin of 1223.1% versus -565.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABEO | TRDA |
|---|---|---|
| Share price | $2.42 | $4.35 |
| Market cap | $165.31M | $170.30M |
| 1-day change | -1.22% | -6.25% |
| YTD return | -54.08% | -57.68% |
| 1-year return | -45.98% | -56.97% |
| 5-year return | -86.74% | -84.95% |
| EPS (TTM) | $-1.16 | $-3.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.82M | $25.42M |
| Revenue growth (YoY) | — | -87.94% |
| Net income (latest FY) | $71.18M | $-143.75M |
| Gross margin | 73.68% | — |
| Operating margin | -1536.91% | -621.13% |
| Net margin | 1223.08% | -565.48% |
| 52-week high | $7.65 | $16.45 |
| 52-week low | $2.09 | $4.11 |
| Distance from 52-week high | -68.37% | -73.56% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +542.98% | +308.05% |
| Average volume | 1.66M | 401.15K |
| Shares outstanding | 68.31M | 39.15M |
| Employees | 226 | 152 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABEO has outperformed TRDA by 11.0 percentage points over the past year.
- Abeona Therapeutics is more profitable, keeping 1223.1 cents of every revenue dollar as net income versus -565.5 cents for Entrada Therapeutics.
About Abeona Therapeutics
ABEO stock →Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 226 employees
About Entrada Therapeutics
TRDA stock →Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 152 employees
ABEO vs TRDA FAQ
Which is bigger, Abeona Therapeutics or Entrada Therapeutics?
Entrada Therapeutics (TRDA) is larger, with a market capitalization of $170.30M compared with $165.31M for Abeona Therapeutics (ABEO).
Which stock has performed better over the past year, ABEO or TRDA?
ABEO returned -45.98% over the past 12 months, compared with -56.97% for TRDA (price return, excluding dividends). Past performance does not predict future results.
Are Abeona Therapeutics and Entrada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.